WeVote
Log In

Bill

Bill

HB 122

Cosmetic products; manufacturing or sale with certain ingredients prohibited.

2026 Regular Session Introduced by Bonita Anthony and 11 co-sponsors

Virginia HB 122 bans certain cosmetic product ingredients from manufacture and sale, passing the House 76-22 and advancing through committee review.

Approved by Governor-Chapter 910 (effective 7/1/2026)
0
WeVote Research Nonpartisan
Bill Summary · HB 122

Legislative bill overview

HB 122 prohibits the manufacturing and sale of cosmetic products containing certain specified ingredients within Virginia. The bill has already passed the House with strong bipartisan support (76-22) and is currently under committee review in what appears to be a 2026 legislative session. The specific ingredients targeted are not detailed in the available action summary, though this type of legislation typically addresses substances like PFOA, phthalates, formaldehyde, or other chemicals banned or restricted in other jurisdictions.

Why this is important

Cosmetic ingredient restrictions directly affect consumer product safety and market access. Virginia's action could influence other states' regulatory approaches and may require manufacturers to reformulate products or create Virginia-specific versions. This reflects growing consumer and regulatory concern about chemical exposure through everyday personal care products, particularly given that federal cosmetic regulation by the FDA is relatively limited compared to other countries.

Potential points of contention

  • Economic burden on manufacturers: Smaller cosmetic companies may face higher compliance costs than large corporations, potentially reducing market competition and consumer choice
  • Market fragmentation: State-level restrictions create conflicting requirements across jurisdictions, forcing manufacturers to maintain multiple product formulations and increasing supply chain complexity
  • Scientific basis uncertainty: Without seeing the specific prohibited ingredients, there's potential debate over whether restrictions are based on peer-reviewed toxicology or precautionary principle, and whether the risk level justifies market restrictions

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.